Quarterly ResultMay 7, 2026, 09:07 AM
MBX Biosciences Q1 Net Loss $(23.5)M; EPS $(0.50); Raises $85M via ATM
AI Summary
MBX Biosciences reported a net loss of $(23.5) million for the first quarter of 2026, an improvement from $(23.9) million in the prior year period, with net loss per share improving to $(0.50). The company significantly bolstered its liquidity by raising $85.0 million in net proceeds through an at-the-market offering in February 2026 and increased its ATM capacity to $250.0 million. As of March 31, 2026, MBX Biosciences held $440.0 million in cash, cash equivalents, and marketable securities, which management believes is sufficient to fund operations for at least 12 months. The company also triggered a $0.1 million milestone payment related to its canvuparatide Phase 2 clinical trial.
Key Highlights
- Net loss for Q1 2026 was $(23.5) million, a slight improvement from $(23.9) million in Q1 2025.
- Net loss per common share improved to $(0.50) in Q1 2026 from $(0.71) in Q1 2025.
- Raised $85.0 million in net proceeds from an at-the-market (ATM) offering in February 2026.
- Increased ATM offering capacity to $250.0 million in March 2026.
- Research and development expenses decreased to $18.5 million in Q1 2026 from $22.4 million in Q1 2025.
- General and administrative expenses increased to $8.8 million in Q1 2026 from $4.1 million in Q1 2025.
- Cash, cash equivalents, and marketable securities totaled $440.0 million as of March 31, 2026.
- Triggered a $0.1 million milestone payment for canvuparatide Phase 2 completion.